15.92
Schlusskurs vom Vortag:
$15.90
Offen:
$15.88
24-Stunden-Volumen:
2.04M
Relative Volume:
0.77
Marktkapitalisierung:
$1.70B
Einnahmen:
$64.52M
Nettoeinkommen (Verlust:
$-95.55M
KGV:
-15.66
EPS:
-1.0169
Netto-Cashflow:
$-84.65M
1W Leistung:
-0.87%
1M Leistung:
-1.12%
6M Leistung:
+140.12%
1J Leistung:
+86.64%
Personalis Inc Stock (PSNL) Company Profile
Firmenname
Personalis Inc
Sektor
Branche
Telefon
650-752-1300
Adresse
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PSNL
Personalis Inc
|
15.92 | 1.70B | 64.52M | -95.55M | -84.65M | -1.0169 |
|
TMO
Thermo Fisher Scientific Inc
|
696.57 | 257.55B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
231.55 | 162.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
NTRA
Natera Inc
|
404.36 | 58.29B | 2.50B | -226.32M | 71.51M | -1.6412 |
|
A
Agilent Technologies Inc
|
175.53 | 49.49B | 7.23B | 1.41B | 1.09B | 4.979 |
|
IQV
Iqvia Holdings Inc
|
271.22 | 44.64B | 16.63B | 1.39B | 2.12B | 8.0674 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-08-24 | Herabstufung | Craig Hallum | Buy → Hold |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-15 | Eingeleitet | Guggenheim | Buy |
| 2025-03-17 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-06 | Hochstufung | Needham | Hold → Buy |
| 2022-01-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | Herabstufung | Needham | Buy → Hold |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-20 | Bestätigt | Needham | Buy |
| 2021-05-06 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-12 | Bestätigt | Needham | Buy |
| 2020-11-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-08 | Eingeleitet | BTIG Research | Buy |
| 2020-08-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2019-09-26 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-07-15 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Personalis Inc Aktie (PSNL) Neueste Nachrichten
Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares - Investing.com
Personalis CFO and COO Aaron Tachibana sells $47,540 in stock - Investing.com
Personalis president & CMO Chen sells $64,847 of PSNL stock - Investing.com
Personalis CEO Christopher Hall sells $120,984 in company stock - Investing.com
Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares - Investing.com Australia
Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares - Investing.com Canada
Personalis CEO Christopher Hall sells $120,984 in company stock By Investing.com - Investing.com Nigeria
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Personalis President and CMO Richard Chen Executes Stock Sale for Tax Withholding - Kalkine Media
Personalis CLO Stephen Michael Moore Sells 2,068 Shares for RSU Tax Withholding - Kalkine Media
Tempus move on Personalis (NASDAQ: PSNL) hinges on cancer tests and data from 50 million patients - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Weekly Recap: Intismeran win and Personalis 13% stake backs Tempus AI - tradingview.com
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation - finance.biggo.com
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels. - WSJ
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Tempus AI shares rise 5.1% to $70 on Moderna cancer trial validation - scanx.trade
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next. - webull.com
Personalis Inc Stock Historical Valuations | FRA:04X - GuruFocus
Personalis Inc Stock Operating Data - GuruFocus
Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? - Yahoo Finance
Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next. - Barchart.com
Why Personalis (PSNL) Is Up 24.0% After New VA MVP Genomics Task Order Win - webull.com
Why Personalis (PSNL) Is Up 24.0% After New VA MVP Genomics Task Order Win - simplywall.st
Personalis falls amid a downgrade as a competitive bid appears unlikely - Seeking Alpha
Tempus AI soars 40% in a week, adding $3.7 billion—over double the Personalis acquisition amount - TechStock²
Tempus AI (TEM) Is Up 39.5% After mRNA Melanoma Trial Win And Personalis DealWhat's Changed - Yahoo Finance
A Look at Personalis Inc (PSNL) After 8.8% Gain -- GF Value $2.4 - GuruFocus
Tempus AI Shares Jump $3 Billion After Moderna Victory Boosts Value of $1.5 Billion Personalis Stake - TechStock²
AMERIPRISE FINANCIAL INC Trims Personalis Inc (PSNL) Stake -- Shares Trade 590% Above GF Value - GuruFocus
Why Tempus AI (TEM) Is Up 22.8% After Buying the Platform Behind a Key mRNA Cancer Win - simplywall.st
Deep Track Capital, LP Trims Personalis Inc (PSNL) Stake -- Shar - GuruFocus
Personalis secures new Million Veteran Program task order - TipRanks
Personalis Receives New Task Order Under U.S. Veterans Affairs Contract For VA MVP - TradingView
Personalis wins up to $18.3M VA MVP task order, cumulative VA awards reach $243.3M - TradingView
Personalis (NASDAQ: PSNL) wins Million Veteran Program task order—how big is it? - Stock Titan
Tempus soars on coattails of Moderna/Merck cancer vaccine - Crain's Chicago Business
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - TradingView
Personalis stock reaches 52-week high at 16.42 USD - Investing.com
Personalis stock reaches 52-week high at 16.42 USD By Investing.com - Investing.com Canada
Tempus AI Just Had Their Entire Strategy Validated By Moderna’s Vaccine Advance (TEM) - Seeking Alpha
TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight - Stocktwits
Personalis | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Personalis Inc : PSNL - 247wallst.com
Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant - Yahoo Finance
Tempus AI Jumps 24% as Merck-Moderna mRNA Vaccine Win Lifts Personalis Deal - finance.biggo.com
TEM Stock Dips As Tempus AI Bets $1.5B On Personalis - StocksToTrade
Personalis Inc. (PSNL) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
Tempus AI Stock Slides As $1.5B Personalis Bet Raises Stakes - timothysykes.com
Finanzdaten der Personalis Inc-Aktie (PSNL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Personalis Inc-Aktie (PSNL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hall Christopher M | Chief Executive Officer |
Sep 18 '26 |
Sale |
16.22 |
7,459 |
120,985 |
228,527 |
| Chen Richard | President and CMO |
Sep 18 '26 |
Sale |
16.22 |
3,998 |
64,848 |
169,882 |
| Tachibana Aaron | CFO AND COO |
Sep 18 '26 |
Sale |
16.22 |
2,931 |
47,541 |
195,902 |
| Chen Richard | President and CMO |
Jul 15 '26 |
Option Exercise |
2.44 |
100,000 |
244,000 |
273,880 |
| Chen Richard | President and CMO |
Jul 15 '26 |
Sale |
15.15 |
100,000 |
1,515,000 |
173,880 |
| RICHARD CHEN | Officer |
Jul 15 '26 |
Proposed Sale |
15.03 |
100,000 |
1,503,000 |
0 |
| Hall Christopher M | Chief Executive Officer |
Jul 09 '26 |
Option Exercise |
1.61 |
100,000 |
161,000 |
335,986 |
| Hall Christopher M | Chief Executive Officer |
Jul 09 '26 |
Sale |
15.08 |
100,000 |
1,508,000 |
235,986 |
| Chris Hall | Director |
Jul 09 '26 |
Proposed Sale |
14.11 |
100,000 |
1,411,000 |
0 |
| Tachibana Aaron | CFO AND COO |
Jun 29 '26 |
Option Exercise |
5.32 |
4,982 |
26,504 |
203,815 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):